Icecure's ice3 5-year trial results published in the peer reviewed annals of surgical oncology journal: prosense® cryoablation without excision for early-stage, low-risk breast cancer demonstrates 96.3% recurrence free rate

Publication comes ahead of the fda advisory panel meeting for marketing authorization of prosense® in early-stage low risk breast cancer scheduled for november 7, 2024 96.3% recurrence free rate for women treated with prosense® cryoablation and endocrine therapy; 100% of patients and treating physicians were satisfied with the cosmetic outcome. lead study author, dr. richard e.
ICE Ratings Summary
ICE Quant Ranking